A Randomized, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986177 (an Oral Anti-thrombotic) With Single and Dual Antiplatelet Therapy (Aspirin and Clopidogrel) in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs Aspirin (Primary) ; BMS 986177 (Primary) ; Clopidogrel (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 23 Jul 2019 Status changed from recruiting to completed.
- 14 Jan 2019 Planned End Date changed from 18 Jan 2019 to 2 Feb 2019.
- 14 Jan 2019 Planned primary completion date changed from 18 Jan 2019 to 2 Feb 2019.